Skip to content
PubMed This is a summary of 95 peer-reviewed journal articles Updated
Hematology

Hemoglobin Lepore-beta-thalassemia syndrome: A Patient Guide

At a Glance

Hemoglobin Lepore-beta-thalassemia syndrome is an inherited blood disorder that can cause mild or severe anemia. Genetic testing distinguishes the syndrome from the usually mild trait, while transfusions, iron checks, and iron-removing medicines can help protect the heart and liver.

Hearing you have a rare blood condition can be overwhelming, especially when the name itself is complex. Hemoglobin Lepore (Hb Lepore) is a rare blood disorder that occupies a middle ground in the world of hematology. It is categorized as both a structural variant—meaning the makeup of the hemoglobin is unusual—and a form of thalassemia, because the body cannot produce enough of it to prevent anemia [1][2].

This dual nature is caused by a specific genetic event called a delta-beta fusion, where two neighboring genes undergo an unequal crossover during reproduction, creating a single “hybrid” instruction manual [3]. Because this hybrid gene is much less efficient at making the beta-globin protein than a healthy gene, the result is a reduction in functional hemoglobin and a variable degree of anemia that closely mimics standard beta-thalassemia [2][4]. (Note: Bracketed codes like [1] refer to the specific published medical literature that supports these facts.)

The impact of Hb Lepore on your daily life depends heavily on your specific genotype, creating a wide spectrum of severity. Most people have the Hb Lepore trait, which means they carry only one copy of the fusion gene alongside one healthy beta-globin gene [5]. For these individuals, the condition is usually mild—they may have no symptoms or only mild anemia, and it may only be discovered during a routine blood test that shows slightly smaller red blood cells (microcytosis) [3].

However, when a person inherits two copies of the Hb Lepore gene, or inherits one Hb Lepore gene along with a beta-thalassemia mutation, they develop Hemoglobin Lepore-beta-thalassemia syndrome [1]. The severity of the syndrome must be assessed individually; it ranges from a moderate anemia that rarely requires intervention (non-transfusion-dependent thalassemia) to severe chronic anemia that requires regular medical intervention (transfusion-dependent thalassemia) [6][7].

For those living with the syndrome, management is built on three essential pillars: managing anemia, managing iron, and consistent monitoring. Patients with a severe phenotype require regular blood transfusions to provide the healthy red blood cells their bodies cannot make, while those with a milder form may only need blood during specific stressful events like a severe illness or pregnancy [8][7]. Because both the disease itself and the transfusions used to treat it can cause iron to build up in the heart and liver, patients may need medications called chelators to remove this excess iron and prevent organ damage [9][10]. Never start iron supplements or chelation without explicit instructions from your hematologist.

Living successfully with Hb Lepore means establishing a long-term relationship with a specialized care team. Because the condition is rare, it can sometimes be misdiagnosed as simple iron deficiency or standard beta-thalassemia [4]. Specialized molecular testing and individualized check-ups are the best tools for ensuring that your treatment stays ahead of potential complications like bone thinning or heart strain [10][11]. With modern management, including advanced iron monitoring and newer therapies, patients with the syndrome can proactively manage their health and protect their vital organs [10][12].

Common questions in this guide

What is Hemoglobin Lepore-beta-thalassemia syndrome?
It is a rare inherited blood disorder caused by a hybrid gene that affects hemoglobin production. The gene makes less functional hemoglobin than usual, so the condition can cause anemia ranging from mild to severe.
How is the Hb Lepore trait different from the syndrome?
The trait usually means a person has one Hb Lepore gene and one healthy beta-globin gene, so there may be no symptoms or only mild anemia and small red blood cells. The syndrome can occur when someone inherits two Hb Lepore genes or one Hb Lepore gene with a beta-thalassemia mutation, leading to more significant anemia.
How is Hb Lepore diagnosed?
Routine blood tests may show anemia or unusually small red blood cells, but these findings can resemble iron deficiency or beta-thalassemia. Specialized molecular or genetic testing can identify the Hb Lepore fusion and clarify whether a person has the trait or the syndrome.
Will I need regular blood transfusions?
Not everyone needs regular transfusions. People with severe, chronic anemia may need them on a regular schedule, while people with milder disease may need blood only during events such as severe illness or pregnancy; a hematologist can determine the appropriate plan.
Why are iron levels monitored in this condition?
Hemoglobin Lepore-beta-thalassemia syndrome and repeated transfusions can cause excess iron to build up in organs such as the heart and liver. A care team may use blood tests and MRI scans to monitor iron and may prescribe iron-removing medicine called chelation when appropriate.
Should I take iron supplements if I have Hb Lepore anemia?
Not unless your hematologist specifically recommends them. Hb Lepore anemia can be mistaken for iron deficiency, so ask your care team to confirm the cause of anemia before taking iron supplements.
How can I plan long-term care for Hb Lepore syndrome?
Long-term care usually includes a hematologist familiar with thalassemia, regular checks of hemoglobin and iron, and monitoring for complications affecting the heart, liver, and bones. A specialized thalassemia center may help coordinate genetic testing, transfusion decisions, and iron monitoring.

Get notified when new evidence is published on Hemoglobin Lepore-beta-thalassemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Homozygous Hemoglobin Lepore: A Rare Condition Seen in a Bangladeshi Family.

    Aziz MA, Khan WA, Das SA, Banu B

    Mymensingh medical journal : MMJ 2021; (30(4)):1172-1176.

    PMID: 34605493
  2. 2

    Biochemical and Molecular Analysis of the Hb Lepore Boston Washington in a Syrian Homozygous Child.

    Pirastru M, Manca L, Trova S, Mereu P

    BioMed research international 2017; (2017()):1261972 doi:10.1155/2017/1261972.

    PMID: 28553644
  3. 3

    Homozygous Lepore Syndrome: A case report.

    Bhusal A, Bhandari S, Seth T, Sah RP

    Annals of medicine and surgery (2012) 2022; (80()):104168 doi:10.1016/j.amsu.2022.104168.

    PMID: 36045803
  4. 4

    Molecular characterization of similar Hb Lepore Boston-Washington in four Chinese families using third generation sequencing.

    Zhuang J, Zhang N, Zheng Y, et al.

    Scientific reports 2024; (14(1)):9966 doi:10.1038/s41598-024-60604-7.

    PMID: 38693200
  5. 5

    Rare occurrence of hemoglobin Lepore variant in a Palestinian patient: a case report and brief literature review.

    Asees MY, Shrateh ON, Jobran AWM, Assi AS

    Annals of medicine and surgery (2012) 2023; (85(10)):5219-5222 doi:10.1097/MS9.0000000000001212.

    PMID: 37811104
  6. 6

    Molecular and clinical analysis of haemoglobin Lepore in Campania, a region of Southern Italy.

    Ricchi P, Ammirabile M, Spasiano A, et al.

    Hematology (Amsterdam, Netherlands) 2017; (22(7)):437-443 doi:10.1080/10245332.2017.1289304.

    PMID: 28218017
  7. 7

    β-Thalassemia Intermedia Caused by Compound Heterozygosity for Hb Lepore-Hollandia and β-Thalassemia is Rare in the Indian Population.

    Sreedharanunni S, Chhabra S, Hira JK, et al.

    Hemoglobin 2015; (39(5)):362-5 doi:10.3109/03630269.2015.1064004.

    PMID: 26291970
  8. 8

    Alpha- and Beta-thalassemia: Rapid Evidence Review.

    Baird DC, Batten SH, Sparks SK

    American family physician 2022; (105(3)):272-280.

    PMID: 35289581
  9. 9

    Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.

    Pinto VM, Forni GL

    International journal of molecular sciences 2020; (21(22)) doi:10.3390/ijms21228771.

    PMID: 33233561
  10. 10

    Increasing prevalence of thalassemia in America: Implications for primary care.

    Sayani FA, Kwiatkowski JL

    Annals of medicine 2015; (47(7)):592-604 doi:10.3109/07853890.2015.1091942.

    PMID: 26541064
  11. 11

    Endocrine dysfunction in homozygous beta-thalassemia: An underrecognized and undertreated consequence of prolonged survival.

    Savvidis C, Ilias I

    World journal of clinical cases 2025; (13(24)):107612 doi:10.12998/wjcc.v13.i24.107612.

    PMID: 40862198
  12. 12

    A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

    Cappellini MD, Viprakasit V, Taher AT, et al.

    The New England journal of medicine 2020; (382(13)):1219-1231 doi:10.1056/NEJMoa1910182.

    PMID: 32212518

This page is for informational purposes only and does not constitute medical advice. A hematologist should interpret your genetic results and guide decisions about transfusions, chelation, and iron monitoring.